These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36405105)

  • 41. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis.
    Chen RP; Zhu Ge XJ; Huang ZM; Ye XH; Hu CY; Lu GR; Lu DY; Phemba IL
    J Clin Gastroenterol; 2014 Mar; 48(3):290-9. PubMed ID: 24030734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts.
    Bercu ZL; Fischman AM; Kim E; Nowakowski FS; Patel RS; Schiano TD; Chang CY; Lookstein RA
    AJR Am J Roentgenol; 2015 Mar; 204(3):654-61. PubMed ID: 25714299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.
    Rajesh S; George T; Philips CA; Ahamed R; Kumbar S; Mohan N; Mohanan M; Augustine P
    World J Gastroenterol; 2020 Oct; 26(37):5561-5596. PubMed ID: 33088154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.
    Horhat A; Bureau C; Thabut D; Rudler M
    United European Gastroenterol J; 2021 Mar; 9(2):203-208. PubMed ID: 32819214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of hernia-related complications after transjugular intrahepatic portosystemic shunt creation in patients with pre-existing ventral abdominal hernias: 15-year experience at a quaternary medical center.
    McDaniel C; Bell R; Farha N; Vozzo C; Bullen J; Rosen M; Romero-Marrero C; Partovi S; Kapoor B
    BMJ Open Gastroenterol; 2022 Mar; 9(1):. PubMed ID: 35318192
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites.
    Williams DB; Waugh R; Selby W
    Aust N Z J Med; 1998 Oct; 28(5):620-6. PubMed ID: 9847951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.
    Heinzow HS; Lenz P; Köhler M; Reinecke F; Ullerich H; Domschke W; Domagk D; Meister T
    World J Gastroenterol; 2012 Oct; 18(37):5211-8. PubMed ID: 23066315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion.
    Tan HK; James PD; Sniderman KW; Wong F
    J Gastroenterol Hepatol; 2015 Feb; 30(2):389-95. PubMed ID: 25168607
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data.
    Nicoară-Farcău O; Han G; Rudler M; Angrisani D; Monescillo A; Torres F; Casanovas G; Bosch J; Lv Y; Thabut D; Fan D; Hernández-Gea V; García-Pagán JC;
    Gastroenterology; 2021 Jan; 160(1):193-205.e10. PubMed ID: 32980344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative TIPS and in-hospital mortality in patients with cirrhosis undergoing surgery.
    Piecha F; Vonderlin J; Frühhaber F; Graß JK; Ozga AK; Harberts A; Benten D; Hübener P; Reeh M; Riedel C; Bannas P; Izbicki JR; Adam G; Huber S; Lohse AW; Kluwe J
    JHEP Rep; 2024 Jan; 6(1):100914. PubMed ID: 38074512
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MELD or Sodium MELD: A Comparison of the Ability of Two Scoring Systems to Predict Outcomes After Transjugular Intrahepatic Portosystemic Shunt Placement.
    Young S; Rostambeigi N; Golzarian J; Lim N
    AJR Am J Roentgenol; 2020 Jul; 215(1):215-222. PubMed ID: 32432911
    [No Abstract]   [Full Text] [Related]  

  • 53. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis.
    Allegretti AS; Ortiz G; Cui J; Wenger J; Bhan I; Chung RT; Thadhani RI; Irani Z
    Am J Kidney Dis; 2016 Sep; 68(3):381-91. PubMed ID: 26994685
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality.
    Lehmann JM; Claus K; Jansen C; Pohlmann A; Schierwagen R; Meyer C; Thomas D; Manekeller S; Claria J; Strassburg CP; Trautwein C; Wasmuth HE; Berres ML; Trebicka J
    Liver Int; 2018 May; 38(5):875-884. PubMed ID: 29105936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of hernia incarceration following transjugular intrahepatic portosystemic shunt placement.
    Smith MT; Rase B; Woods A; Trotter J; Gipson M; Kondo K; Ray C; Durham J
    J Vasc Interv Radiol; 2014 Jan; 25(1):58-62. PubMed ID: 24269791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.
    Lee HL; Lee SW
    Clin Mol Hepatol; 2022 Apr; 28(2):121-134. PubMed ID: 34571587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incrementally Expandable Transjugular Intrahepatic Portosystemic Shunts: Single-Center Experience.
    Cui J; Smolinski SE; Liu F; Xu D; Dulaimy K; Irani Z
    AJR Am J Roentgenol; 2018 Feb; 210(2):438-446. PubMed ID: 29261352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeted decrease of portal hepatic pressure gradient improves ascites control after TIPS.
    Queck A; Schwierz L; Gu W; Ferstl PG; Jansen C; Uschner FE; Praktiknjo M; Chang J; Brol MJ; Schepis F; Merli M; Strassburg CP; Lehmann J; Meyer C; Trebicka J
    Hepatology; 2023 Feb; 77(2):466-475. PubMed ID: 35869810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transjugular Intrahepatic Portosystemic Shunts in Patients with Cirrhosis with Refractory Ascites: Comparison of Clinical Outcomes by Using 8- and 10-mm PTFE-covered Stents.
    Miraglia R; Maruzzelli L; Tuzzolino F; Petridis I; D'Amico M; Luca A
    Radiology; 2017 Jul; 284(1):281-288. PubMed ID: 28121521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.